Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The clinical-stage biotech released fourth-quarter and full-year earnings.
Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.